Top 10 Companies in the Pharmaceutical-grade HFA-134a Market (2026): Key Players Behind Advanced Inhalation Therapies

In Business Insights
March 03, 2026


The Global Pharmaceutical-grade HFA-134a Market was valued at USD 752 Million in 2025 and is projected to reach USD 1,242 Million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period (2025–2034). This growth is being driven by the rising global incidence of respiratory diseases like asthma and COPD, the global phase-out of CFC-based propellants, and stringent pharmacopoeial standards for inhaled drug delivery systems.

As the pharmaceutical industry advances toward safer and more effective pulmonary therapies, the essential role of high-purity propellants is undeniable. These critical components are supplied by a select group of specialized chemical manufacturers who ensure the safety, efficacy, and reliability of millions of metered-dose inhalers (MDIs) worldwide. In this blog, we profile the Top 10 Companies in the Pharmaceutical-grade HFA-134a Industry—global leaders in fluorochemical production and purification, whose stringent quality controls are vital for global respiratory health.


🔟 1. SRF Limited

Headquarters: Gurugram, Haryana, India
Key Offering: USP/EP Grade HFA-134a (≥99.97% purity)

SRF Limited is a leading global manufacturer of fluorochemicals and a major supplier of pharmaceutical-grade HFA-134a. Its technical textiles and packaging films division supports a diversified business model, but its fluorochemicals segment is critical for producing the high-purity propellant used in MDIs for leading pharmaceutical companies worldwide.

Quality and Expansion Initiatives:

  • Investment in state-of-the-art purification technologies to exceed USP and EP standards.

  • Strategic capacity expansions to meet rising global demand for inhalation therapies.

  • Strong focus on supply chain resilience and long-term contracts with major pharmaceutical firms.

Download FREE Sample Report: Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report


9️⃣ 2. Koura (A GC company)

Headquarters: London, United Kingdom
Key Offering: Zephex® Pharma propellants (incl. HFA-134a)

Koura, a global leader in the manufacture and supply of fluoroproducts, is a key player in the pharmaceutical propellant market. Its Zephex® Pharma brand is recognized for high-purity HFA-134a, specifically engineered for MDI applications. Koura’s vertically integrated operations, from fluorine production to final purification, ensure a secure and consistent supply.

Quality and Expansion Initiatives:

  • Global production footprint with facilities in the US and Europe, ensuring supply security.

  • Continuous R&D to enhance purity levels and develop next-generation, low-GWP propellants.


8️⃣ 3. Zhejiang Juhua Co., Ltd.

Headquarters: Quzhou, Zhejiang, China
Key Offering: Pharmaceutical-grade HFA-134a

Juhua Group is a major Chinese chemical enterprise and a significant supplier in the Asian pharmaceutical-grade HFA-134a market. Leveraging its extensive fluorochemical production capabilities, Juhua provides high-purity propellants to both domestic and international pharmaceutical manufacturers, playing a crucial role in the region’s growing respiratory care sector.

Quality and Expansion Initiatives:

  • Focus on scaling production to cater to the rapidly expanding Asia-Pacific market.

  • Investment in quality control systems to meet international regulatory standards.


7️⃣ 4. The Chemours Company

Headquarters: Wilmington, Delaware, USA
Key Offering: Opteon™ and other high-purity fluorochemicals

While historically known for its refrigerants, Chemours possesses deep expertise in fluorotechnology that is applicable to pharmaceutical propellants. The company’s focus on innovation and sustainability positions it as a potential key player in developing and supplying next-generation, environmentally friendly propellants for the pharmaceutical industry.

Quality and Expansion Initiatives:

  • R&D leadership in fluorochemistry for sustainable solutions.

  • Strong intellectual property portfolio related to fluorinated compounds.

Download FREE Sample Report: Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report


6️⃣ 5. Arkema S.A.

Headquarters: Colombes, France
Key Offering: High-performance fluorogases and specialty chemicals

Arkema is a global chemical leader with a strong fluorochemicals division. The company’s advanced material science expertise makes it a relevant and capable supplier for high-purity ingredients, including those required for pharmaceutical applications. Its global presence supports a reliable supply chain for European and international markets.

Quality and Expansion Initiatives:

  • Commitment to sustainable chemistry and product innovation.

  • Strategic focus on high-value, specialized market segments.


5️⃣ 6. Daikin Industries, Ltd.

Headquarters: Osaka, Japan
Key Offering: Fluorochemicals including HFA-134a

Daikin, a world leader in air conditioning, is also a major producer of fluorochemicals. The company’s sophisticated chemical synthesis and purification technologies provide a foundation for producing pharmaceutical-grade materials. Daikin’s stringent quality control is critical for serving the exacting Japanese pharmaceutical market and beyond.

Quality and Expansion Initiatives:

  • Investment in R&D for new fluorinated molecules with improved environmental profiles.

  • Robust quality management systems aligned with global Good Manufacturing Practice (GMP).


4️⃣ 7. Solvay S.A.

Headquarters: Brussels, Belgium
Key Offering: Specialty polymers and fluorinated compounds

Solvay’s legacy in specialty chemicals includes deep knowledge of fluorine chemistry. While its current focus may be on other high-growth areas, its technical capabilities and global infrastructure position it as a potential entrant or specialized supplier in the high-purity pharmaceutical propellant space, particularly for complex formulations.

Quality and Expansion Initiatives:

  • Expertise in developing customized solutions for demanding industrial and pharmaceutical applications.

  • Strong global regulatory and compliance expertise.


3️⃣ 8. Honeywell International Inc.

Headquarters: Charlotte, North Carolina, USA
Key Offering: Solstice® hydrofluoroolefin (HFO) and other fluorinated products

Honeywell is a leader in developing low-global-warming-potential technologies, including its Solstice® HFO platform. This focus on next-generation fluorinated compounds makes Honeywell a pivotal player in the future of inhalation propellants, as the industry seeks sustainable alternatives to HFA-134a with similar performance and safety profiles.

Quality and Expansion Initiatives:

  • Pioneering R&D in low-GWP propellants for various applications, including medical aerosols.

  • Building partnerships with pharmaceutical companies to qualify new, environmentally friendly propellants.


2️⃣ 9. Sinochem Lantian Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Fluorochemicals and refrigerants

As part of the Sinochem Group, one of China’s largest state-owned chemical companies, Sinochem Lantian has significant resources and production capacity in fluorochemicals. It is a key domestic supplier for various industries and is strategically positioned to serve the growing Chinese pharmaceutical market’s need for high-purity HFA-134a.

Quality and Expansion Initiatives:

  • Expanding purification capabilities to meet pharmaceutical standards.

  • Leveraging domestic market strength to build a global presence.


1️⃣ 10. Mexichem S.A.B. de C.V. (Orbia)

Headquarters: Mexico City, Mexico
Key Offering: Fluoroproducts and vinyls

Orbia’s fluorinated solutions business has historically been involved in the production of fluorochemicals. Its manufacturing capabilities and geographic location provide a strategic supply source for North and South American markets. The company’s focus on infrastructure and precision materials underpins its potential in specialized chemical production.

Quality and Expansion Initiatives:

  • Focus on operational excellence and supply chain efficiency.

  • Investment in technologies to enhance product purity and performance.

Get Full Report Here: Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report


🌍 Outlook: The Future of Inhalation Propellants Is Purer and More Sustainable

The pharmaceutical-grade HFA-134a market is undergoing a significant evolution. While it remains the workhorse propellant for MDIs, the industry is actively investing in ultra-high-purity production and the development of next-generation, low-GWP alternatives to address environmental concerns.

📈 Key Trends Shaping the Market:

  • Increasing demand for ≥99.99% purity grades to ensure drug stability and patient safety.

  • Accelerated R&D into hydrofluoroolefins (HFOs) and other propellants with negligible Global Warming Potential.

  • Regulatory pressure and industry initiatives to reduce the carbon footprint of inhalation therapies.

  • Strategic partnerships between propellant manufacturers and pharmaceutical companies to co-develop new formulations.

Get Full Report Here: Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

The companies listed above are not only supplying a critical component for respiratory medicine—they are at the forefront of innovation and quality assurance that protects patient health and drives the industry toward a more sustainable future.